Abstract

Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol

Author(s): Snyder Scott, Listecki Robert E

Issue: Sep/Oct 2012 - Volume 16, Number 5

Page(s): 376-380

Download in electronic PDF format for $75
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 1
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 2
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 3
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 4
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 5

Note: Electronic version includes supplemental material.

Abstract

Effective thyroid replacement therapy may be elusive to some patients, and compounding pharmacists have an opportunity to deliver more effective therapy. Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th edition states that the body usually secretes T4:T3 in an 11:1 ratio but cautions against pursuing combined thyroid replacement due to the short halflife of T3 that necessitates multiple daily dosing; no commercial availability and lack of benefit were shown in trials.1 Commercial combinations of T4/T3 such as Armour Thyroid and Nature-Thyroid have a 4.22:1 T4:T3 ratio. Applying the same concept as bioidentical hormone replacement therapy, compounding pharmacists can deliver an 11:1 ratio using a commercial T4 product and taking into account oral bioavailability of each entity. The short half-life of T3 can be remedied by taking the patient’s daily T3 dose and dividing it into two slow-release capsules to be dosed every 12 hours.

Related Keywords

  • thyroid hormone deficiency
  • hypothyroidism
  • thyroid replacement
  • oral bioavailability
  • slow-release preparation
  • literature review
  • combination T4/T3 therapy
  • formulation
  • levothyroxine
  • T4
  • liothyronine
  • T3

Related Categories

  • FORMULATIONS
  • HRT
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
  • LITERATURE REVIEW
  • PATIENT ASSESSMENT

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2012
Pg. 376-380
Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol
Author(s): Snyder Scott, Listecki Robert E
Jul/Aug 2005
Pg. 268-273
Hypothyroidism: Optimizing Therapy with Slow-Release Compounded Thyroid Replacement
Author(s): Milner Martin
Sep/Oct 2017
Pg. 418-425
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Author(s): Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Nov/Dec 2008
Pg. 545
Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules
Author(s): Allen Loyd V Jr
Jul/Aug 2010
Pg. 306-309
Thyroid Potency Calculations
Author(s): Stack Bob
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Mar/Apr 2010
Pg. 165-170
Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study
Author(s): Moro Doris, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah
Nov/Dec 2008
Pg. 547
Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2008
Pg. 548
Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 250-256
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Author(s): Gillson George R, Zava David T
Jan/Feb 2002
Pg. 50-54
Bioidentical Hormone Replacement Therapy, Part 2, A Review of
Author(s): Wepfer Scott T
Nov/Dec 2008
Pg. 488-497
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Author(s): Paoletti Jim
Jan/Feb 2024
Pg. 34-43
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Author(s): Paoletti Jim
Jan/Feb 2001
Pg. 52-54
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Author(s): Ford Gina, Garcia Lea
Mar/Apr 2002
Pg. 142-146
Bioidentical Hormone Replacement Therapy, Part 3, A Review of
Author(s): Wepfer Scott T
Jul/Aug 2004
Pg. 313-319
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2005
Pg. 266
Guidelines for Consulting with Patients about Bioidentical Hormone Replacement Therapy
Author(s): White Irene Q
Nov/Dec 2016
Pg. 447-454
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Author(s): Deleruyelle Laura J
Sep/Oct 2016
Pg. 359-364
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Author(s): Deleruyelle Laura J
Jul/Aug 2011
Pg. 290-300
Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review
Author(s): Ruiz Andres D, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R